PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
66.07%
EBIT growth of 66.07% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
66.07%
Operating income growth of 66.07% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
71.07%
Net income growth of 71.07% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
71.05%
EPS growth of 71.05% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
71.05%
Diluted EPS growth of 71.05% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.38%
Share reduction while Healthcare median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-0.38%
Diluted share reduction while Healthcare median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
46.07%
OCF growth of 46.07% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
46.07%
FCF growth of 46.07% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-264.77%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-264.77%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-264.77%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
78.58%
Net income/share CAGR of 78.58% while Healthcare median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
78.58%
Net income/share CAGR of 78.58% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
78.58%
3Y net income/share CAGR of 78.58% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
-13.10%
Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-13.10%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-13.10%
Negative 3Y equity/share growth while Healthcare median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.75%
AR shrinking while Healthcare median grows. Seth Klarman sees potential advantage unless it signals declining demand.
No Data
No Data available this quarter, please select a different quarter.
-5.84%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-1.56%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-66.07%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.